Source: Annual Congress 2005 - Treatment of respiratory infections
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. E. Makarevich, J. J. Pancratova, B. V. Kirkovsky (Minsk, Belarus). Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA). Eur Respir J 2005; 26: Suppl. 49, 4050

Member's Comments

No comment yet.

Related content which might interest you: The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 The correction of oxydant-antioxidant imbalance in severe community-acquired pneumonia (CAP) by extracorporeal efferent detoxication methods (EEDM) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 The improvement of protease-inhibitor imbalance in severe community-acquired pneumonia (CAP) by extracorporeal efferent detoxication methods (EEDM) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 A simple method for determining the time of conversion to oral antibiotic therapy in community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 The correction of immune disorders by extracorporeal efferent detoxication methods (EEDM) in severe community-acquired pneumonia (CAP) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP) Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019 Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007 Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012